<?xml version='1.0' encoding='utf-8'?>
<document id="10945310"><sentence text="Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein."><entity charOffset="24-31" id="DDI-PubMed.10945310.s1.e0" text="digoxin" /><entity charOffset="47-56" id="DDI-PubMed.10945310.s1.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.10945310.s1.e0" e2="DDI-PubMed.10945310.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10945310.s1.e0" e2="DDI-PubMed.10945310.s1.e1" /></sentence><sentence text="Recent data indicated that disposition of oral digoxin is modulated by intestinal P-glycoprotein"><entity charOffset="47-54" id="DDI-PubMed.10945310.s2.e0" text="digoxin" /></sentence><sentence text=" The cardioselective beta-blocker talinolol has been described to be secreted by way of P-glycoprotein into the lumen of the gastrointestinal tract after oral and intravenous administration"><entity charOffset="34-43" id="DDI-PubMed.10945310.s3.e0" text="talinolol" /></sentence><sentence text=" We therefore hypothesized that coadministration of digoxin and talinolol may lead to a drug-drug interaction based on a competition for intestinal P-glycoprotein"><entity charOffset="52-59" id="DDI-PubMed.10945310.s4.e0" text="digoxin" /><entity charOffset="64-73" id="DDI-PubMed.10945310.s4.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.10945310.s4.e0" e2="DDI-PubMed.10945310.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10945310.s4.e0" e2="DDI-PubMed.10945310.s4.e1" /></sentence><sentence text="" /><sentence text="Pharmacokinetics of digoxin (0"><entity charOffset="20-27" id="DDI-PubMed.10945310.s6.e0" text="digoxin" /></sentence><sentence text="5 mg orally), talinolol (30 mg intravenously and 100 mg orally), and digoxin plus talinolol orally, as well as digoxin plus talinolol intravenously, were assessed in five male and five female healthy volunteers (age range, 23 to 30 years; body weight, 60 to 95 kg) in a changeover study with at least a 7-day washout period"><entity charOffset="14-23" id="DDI-PubMed.10945310.s7.e0" text="talinolol" /><entity charOffset="69-76" id="DDI-PubMed.10945310.s7.e1" text="digoxin" /><entity charOffset="82-91" id="DDI-PubMed.10945310.s7.e2" text="talinolol" /><entity charOffset="111-118" id="DDI-PubMed.10945310.s7.e3" text="digoxin" /><entity charOffset="124-133" id="DDI-PubMed.10945310.s7.e4" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e0" e2="DDI-PubMed.10945310.s7.e0" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e0" e2="DDI-PubMed.10945310.s7.e1" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e0" e2="DDI-PubMed.10945310.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e0" e2="DDI-PubMed.10945310.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e0" e2="DDI-PubMed.10945310.s7.e4" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e1" e2="DDI-PubMed.10945310.s7.e1" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e1" e2="DDI-PubMed.10945310.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e1" e2="DDI-PubMed.10945310.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e1" e2="DDI-PubMed.10945310.s7.e4" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e2" e2="DDI-PubMed.10945310.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e2" e2="DDI-PubMed.10945310.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e2" e2="DDI-PubMed.10945310.s7.e4" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e3" e2="DDI-PubMed.10945310.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10945310.s7.e3" e2="DDI-PubMed.10945310.s7.e4" /></sentence><sentence text=" Digoxin and talinolol were analyzed by fluorescence polarization immunoassay and HPLC, respectively"><entity charOffset="1-8" id="DDI-PubMed.10945310.s8.e0" text="Digoxin" /><entity charOffset="13-22" id="DDI-PubMed.10945310.s8.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.10945310.s8.e0" e2="DDI-PubMed.10945310.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10945310.s8.e0" e2="DDI-PubMed.10945310.s8.e1" /></sentence><sentence text="" /><sentence text="Oral coadministration of 100 mg talinolol increased the area under the concentration-time curve (AUC) from 0 to 6 hours and the AUC from 0 to 72 hours of digoxin significantly by 18% and 23%, respectively (5"><entity charOffset="32-41" id="DDI-PubMed.10945310.s10.e0" text="talinolol" /><entity charOffset="154-161" id="DDI-PubMed.10945310.s10.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10945310.s10.e0" e2="DDI-PubMed.10945310.s10.e0" /><pair ddi="false" e1="DDI-PubMed.10945310.s10.e0" e2="DDI-PubMed.10945310.s10.e1" /></sentence><sentence text="85+/-1" /><sentence text="49 versus 7" /><sentence text="22+/-1" /><sentence text="29 ng x h/mL and 23" /><sentence text="0+/-3" /><sentence text="3 versus 27" /><sentence text="1+/-3" /><sentence text="7 ng x h/mL, for both P&lt;" /><sentence text="05) and the maximum serum levels by 45%" /><sentence text=" Renal clearance and half-life of digoxin remained unchanged"><entity charOffset="34-41" id="DDI-PubMed.10945310.s20.e0" text="digoxin" /></sentence><sentence text=" Coinfusion of 30 mg talinolol with oral digoxin had no significant effects on digoxin pharmacokinetics"><entity charOffset="21-30" id="DDI-PubMed.10945310.s21.e0" text="talinolol" /><entity charOffset="41-48" id="DDI-PubMed.10945310.s21.e1" text="digoxin" /><entity charOffset="79-86" id="DDI-PubMed.10945310.s21.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.10945310.s21.e0" e2="DDI-PubMed.10945310.s21.e0" /><pair ddi="false" e1="DDI-PubMed.10945310.s21.e0" e2="DDI-PubMed.10945310.s21.e1" /><pair ddi="false" e1="DDI-PubMed.10945310.s21.e0" e2="DDI-PubMed.10945310.s21.e2" /><pair ddi="false" e1="DDI-PubMed.10945310.s21.e1" e2="DDI-PubMed.10945310.s21.e1" /><pair ddi="false" e1="DDI-PubMed.10945310.s21.e1" e2="DDI-PubMed.10945310.s21.e2" /></sentence><sentence text=" Digoxin did not affect the disposition of talinolol after both oral and intravenous administration"><entity charOffset="1-8" id="DDI-PubMed.10945310.s22.e0" text="Digoxin" /><entity charOffset="43-52" id="DDI-PubMed.10945310.s22.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.10945310.s22.e0" e2="DDI-PubMed.10945310.s22.e0" /><pair ddi="false" e1="DDI-PubMed.10945310.s22.e0" e2="DDI-PubMed.10945310.s22.e1" /></sentence><sentence text="" /><sentence text="We observed a significantly increased bioavailability of digoxin with oral coadministration of talinolol, which is most likely caused by competition for intestinal P-glycoprotein"><entity charOffset="57-64" id="DDI-PubMed.10945310.s24.e0" text="digoxin" /><entity charOffset="95-104" id="DDI-PubMed.10945310.s24.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.10945310.s24.e0" e2="DDI-PubMed.10945310.s24.e0" /><pair ddi="false" e1="DDI-PubMed.10945310.s24.e0" e2="DDI-PubMed.10945310.s24.e1" /></sentence><sentence text="" /></document>